Needham analyst Scott Berg maintains SPS Commerce (NASDAQ:SPSC) with a Buy and lowers the price target from $200 to $150.
Humanigen’s Lenzilumab Disappoints In NIH-Backed COVID-19 Study
Humanigen Inc (NASDAQ: HGEN) has been informed of preliminary topline results from the ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients.